SARS-CoV-2 DNA Vaccine (Immuno Cure 3/University of Hong Kong)

N/A

Report date: 2023/08/04 17:14:58

Base Information

Drug NameSARS-CoV-2 DNA Vaccine (Immuno Cure 3/University of Hong Kong)
Drug Alias Name埃斯克福ICCOV based on PD-1-enhanced DNA vaccine platform(Immuno Cure 3/University of Hong Kong)ICCOVIMC-002
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryHong Kong
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Hong KongImmuno Cure 3 Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Hong KongImmuno Cure 3 Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A